Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Share this content:
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.

Title: Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer1

Principal Investigator: Maheswari Senthil, MD, Loma Linda University Cancer Center

Description: For this open-label phase 1 study (ClinicalTrials.gov Identifier: NCT02672865), researchers are evaluating the feasibility and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced gastric cancer.

Eligible patients will have their abdominal cavity bathed in a 40° to 42° Celsius solution of mitomycin 15 mg/m2 and cisplatin 50 mg/m2 for 90 minutes after surgical resection.

The primary outcome is post-operative complications, for which patients will be monitored for 90 days. A modified Clavien-Dindo classification will be used to grade any complications that occur.

The estimated study enrollment is 15 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02672865.

Status: Open and recruiting patients as of December 15, 2017.

This study is sponsored by Loma Linda University.

Reference

  1. ClinicalTrials.gov. Adjuvant hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer. NCT02672865. https://clinicaltrials.gov/ct2/show/NCT02672865. Accessed December 15, 2017. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs